Sirtuin-6-dependent genetic and epigenetic alterations are associated with poor clinical outcome in hepatocellular carcinoma patients

Hepatology

Volumn 58, Issue 3, 2013, Pages 1054-1064

  Marquardt, Jens U ^a   Fischer, Kerstin ^a   Baus, Katharina ^a   Kashyap, Anubha ^a   Ma, Shengyun ^a   Krupp, Markus ^a   Linke, Matthias ^b   Teufel, Andreas ^a   Zechner, Ulrich ^b   Strand, Dennis ^a   Thorgeirsson, Snorri S ^a   Galle, Peter R ^a   Strand, Susanne ^a  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA FETOPROTEIN; FAS ANTIGEN; GLYPICAN 3; RNA H19; SIRTUIN 6; SOMATOMEDIN B;

ADULT; ANIMAL CELL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER PATIENT; CANCER PROGNOSIS; CELL ISOLATION; CELL STIMULATION; CONTROLLED STUDY; DNA METHYLATION; DOWN REGULATION; EPIGENETICS; FEMALE; GENE EXPRESSION; HEPATOMA CELL; HUMAN; HUMAN CELL; HYPOGLYCEMIA; LIPID STORAGE; LIVER CELL; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; MICROARRAY ANALYSIS; MOUSE; NONHUMAN; OUTCOME ASSESSMENT; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTEIN EXPRESSION; UPREGULATION;

AGED; AGED, 80 AND OVER; ANIMALS; CARCINOMA, HEPATOCELLULAR; CELLS, CULTURED; DISEASE PROGRESSION; DOWN-REGULATION; EPIGENESIS, GENETIC; FEMALE; HUMANS; LIVER NEOPLASMS; MALE; MICE; MICE, KNOCKOUT; MIDDLE AGED; OXIDATIVE STRESS; PROGNOSIS; SIGNAL TRANSDUCTION; SIRTUINS; SURVIVAL RATE;

EID: 84883223984     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.26413     Document Type: Article

References (40)

1. El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 2007;132:2557-2576.
2. Sherman M. Hepatocellular carcinoma: epidemiology, surveillance, and diagnosis. Semin Liver Dis 2009;30:3-16.
3. Paradis V, Zalinski S, Chelbi E, Guedj N, Degos F, Vilgrain V, et al. Hepatocellular carcinomas in patients with metabolic syndrome often develop without significant liver fibrosis: a pathological analysis. Hepatology 2009;49:851-859.
4. Cohen JC, Horton JD, Hobbs HH. Human fatty liver disease: old questions and new insights. Science 2011;332:1519-1523.
5. Elsharkawy AM, Mann DA. Nuclear factor-kappaB and the hepatic inflammation-fibrosis-cancer axis. Hepatology 2007;46:590-597.
6. Pan PW, Feldman JL, Devries MK, Dong A, Edwards AM, Denu JM. Structure and biochemical functions of SIRT6. J Biol Chem 2011;286:14575-14587.
7. Zhong L, D'Urso A, Toiber D, Sebastian C, Henry RE, Vadysirisack DD, et al. The histone deacetylase Sirt6 regulates glucose homeostasis via Hif1alpha. Cell 2010;140:280-293.
8. Kawahara TL, Michishita E, Adler AS, Damian M, Berber E, Lin M, et al. SIRT6 links histone H3 lysine 9 deacetylation to NF-kappaB-dependent gene expression and organismal life span. Cell 2009;136:62-74.
9. Mostoslavsky R, Chua KF, Lombard DB, Pang WW, Fischer MR, Gellon L, et al. Genomic instability and aging-like phenotype in the absence of mammalian SIRT6. Cell 2006;124:315-329.
10. Xiao C, Kim HS, Lahusen T, Wang RH, Xu X, Gavrilova O, et al. SIRT6 deficiency results in severe hypoglycemia by enhancing both basal and insulin-stimulated glucose uptake in mice. J Biol Chem 2010;285:36776-36784.
11. Kim HS, Xiao C, Wang RH, Lahusen T, Xu X, Vassilopoulos A, et al. Hepatic-specific disruption of SIRT6 in mice results in fatty liver formation due to enhanced glycolysis and triglyceride synthesis. Cell Metab 2010;12:224-236.
12. Karin M. Nuclear factor-kappaB in cancer development and progression. Nature 2006;441:431-436.
13. Chen LF, Fischle W, Verdin E, Greene WC. Duration of nuclear NF-kappaB action regulated by reversible acetylation. Science 2001;293:1653-1657.
14. Kawahara TL, Rapicavoli NA, Wu AR, Qu K, Quake SR, Chang HY. Dynamic chromatin localization of Sirt6 shapes stress- and aging-related transcriptional networks. PLoS Genet 2011;7:e1002153.
15. Natoli G. When sirtuins and NF-kappaB collide. Cell 2009;136:19-21.
16. Lee JS, Chu IS, Mikaelyan A, Calvisi DF, Heo J, Reddy JK, et al. Application of comparative functional genomics to identify best-fit mouse models to study human cancer. Nat Genet 2004;36:1306-1311.
17. Lee JS, Grisham JW, Thorgeirsson SS. Comparative functional genomics for identifying models of human cancer. Carcinogenesis 2005;26:1013-1020.
18. Lee JS, Thorgeirsson SS. Comparative and integrative functional genomics of HCC. Oncogene 2006;25:3801-3809.
19. Teufel A, Maass T, Strand S, Kanzler S, Galante T, Becker K, et al. Liver-specific Ldb1 deletion results in enhanced liver cancer development. J Hepatol 2010;53:1078-1084.
20. Li W, Liu M. Distribution of 5-hydroxymethylcytosine in different human tissues. J Nucleic Acids 2011;2011:870726.
21. Lee JS, Chu IS, Heo J, Calvisi DF, Sun Z, Roskams T, et al. Classification and prediction of survival in hepatocellular carcinoma by gene expression profiling. Hepatology 2004;40:667-676.
22. Andersen JB, Factor VM, Marquardt JU, Raggi C, Lee YH, Seo D, et al. An integrated genomic and epigenomic approach predicts therapeutic response to zebularine in human liver cancer. Sci Transl Med 2010;2:54ra77.
23. Rhodes DR, Yu J, Shanker K, Deshpande N, Varambally R, Ghosh D, et al. ONCOMINE: a cancer microarray database and integrated data-mining platform. Neoplasia 2004;6:1-6.
24. Michishita E, McCord RA, Berber E, Kioi M, Padilla-Nash H, Damian M, et al. SIRT6 is a histone H3 lysine 9 deacetylase that modulates telomeric chromatin. Nature 2008;452:492-496.
25. Rodgers JT, Puigserver P. Certainly can't live without this: SIRT6. Cell Metab 2006;3:77-78.
26. Calvisi DF, Ladu S, Gorden A, Farina M, Lee JS, Conner EA, et al. Mechanistic and prognostic significance of aberrant methylation in the molecular pathogenesis of human hepatocellular carcinoma. J Clin Invest 2007;117:2713-2722.
27. Sebastian C, Zwaans BM, Silberman DM, Gymrek M, Goren A, Zhong L, et al. The histone deacetylase SIRT6 is a tumor suppressor that controls cancer metabolism. Cell 2012;151:1185-1199.
28. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011;144:646-674.
29. Min L, Ji Y, Bakiri L, Qiu Z, Cen J, Chen X, et al. Liver cancer initiation is controlled by AP-1 through SIRT6-dependent inhibition of survivin. Nat Cell Biol 2012;14:1203-1211.
30. Marquardt JU, Galle PR, Teufel A. Molecular diagnosis and therapy of hepatocellular carcinoma (HCC); an emerging field for advanced technologies. J Hepatol 2012;56:267-275.
31. Greenbaum LE. Cell cycle regulation and hepatocarcinogenesis. Cancer Biol Ther 2004;3:1200-1207.
32. Min L, He B, Hui L. Mitogen-activated protein kinases in hepatocellular carcinoma development. Semin Cancer Biol 2011;21:10-20.
33. Szakacs G, Paterson JK, Ludwig JA, Booth-Genthe C, Gottesman MM. Targeting multidrug resistance in cancer. Nat Rev Drug Discov 2006;5:219-234.
34. Villanueva A, Newell P, Chiang DY, Friedman SL, Llovet JM. Genomics and signaling pathways in hepatocellular carcinoma. Semin Liver Dis 2007;27:55-76.
35. Breuhahn K, Longerich T, Schirmacher P. Dysregulation of growth factor signaling in human hepatocellular carcinoma. Oncogene 2006;25:3787-3800.
36. Tovar V, Alsinet C, Villanueva A, Hoshida Y, Chiang DY, Sole M, et al. IGF activation in a molecular subclass of hepatocellular carcinoma and pre-clinical efficacy of IGF-1R blockage. J Hepatol 2010;52:550-559.
37. Feinberg AP, Tycko B. The history of cancer epigenetics. Nat Rev Cancer 2004;4:143-153.
38. Herceg Z, Paliwal A. Epigenetic mechanisms in hepatocellular carcinoma: how environmental factors influence the epigenome. Mutat Res 2011;727:55-61.
39. Um TH, Kim H, Oh BK, Kim MS, Kim KS, Jung G, et al. Aberrant CpG island hypermethylation in dysplastic nodules and early HCC of hepatitis B virus-related human multistep hepatocarcinogenesis. J Hepatol 2011;54:939-947.
40. Mas VR, Maluf DG, Archer KJ, Yanek K, Kong X, Kulik L, et al. Genes involved in viral carcinogenesis and tumor initiation in hepatitis C virus-induced hepatocellular carcinoma. Mol Med 2009;15:85-94.